Merck Q2 Earnings Preview: Analyst Expectations, Jim Cramer's View, And The Spotlight On Keytruda
Portfolio Pulse from Chris Katje
Merck & Company (NYSE:MRK) is set to report its Q2 financial results, with analysts expecting a revenue of $14.387 billion and a loss of $2.17 per share. The company's Keytruda cancer immunotherapy is in focus, with recent trial results suggesting further applications and increased revenue possibilities. Merck has also reported data from two late-stage studies for its pneumococcal conjugate vaccine and results from a midstage trial for a cancer vaccine being developed with Moderna Inc (NASDAQ:MRNA).
July 31, 2023 | 4:34 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Merck's Q2 results are expected to show a loss, but the focus is on its Keytruda cancer immunotherapy which could boost future revenues.
While Merck is expected to report a loss for Q2, the potential of its Keytruda cancer immunotherapy and other products could positively impact future revenues and investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Moderna is developing a cancer vaccine with Merck, which could potentially expand their vaccine work into other types of cancer.
Moderna's collaboration with Merck on a cancer vaccine could potentially expand their vaccine work into other types of cancer, which could positively impact Moderna's future revenues and stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50